People living with depression who use psilocybin are not abandoning conventional mental health care, according to a new nationally representative study from researchers at the University of California San Diego School of Medicine. The findings, published online in the journal Psychological Medicine, indicate that people with depression who use the psychedelic compound seek professional mental health services at rates comparable to those who do not use it.
That result pushes back against a widely voiced concern among clinicians: that as psilocybin decriminalization gains momentum across the United States, patients might walk away from supervised therapy and prescription treatment in favor of self-medicating with mushrooms. At least at the population level, the new data suggest that kind of wholesale substitution is not occurring.
A Nationally Representative Look at the Question
Until now, the debate over psilocybin and treatment dropout rested largely on anecdote and clinical observation. There was no nationally representative evidence showing whether people with depression who use psilocybin actually disengage from the mental health system. The UC San Diego team set out to fill that gap.
The researchers analyzed data from the 2024 National Survey on Drug Use and Health (NSDUH), a large federal survey that tracks substance use and mental health indicators across the U.S. population. The 2024 edition was notable for a methodological change: it was the first iteration of the survey to specifically record how recently a respondent had used psilocybin, not just whether they had ever used it at any point in their lives.
That distinction matters. Knowing that someone tried psilocybin years ago says little about their current relationship with mental health care. Knowing they used it within the past year, by contrast, allows researchers to examine how that recent use lines up with present-day engagement in treatment — a much more relevant question for clinicians and policymakers.
The analysis focused on 6,793 individuals ages 12 and older who reported experiencing a major depressive episode within the past year. Among that group, an estimated 7.3% reported psilocybin use, according to the study's findings.
Why Clinicians Feared a Drop-Off in Care
The concern driving the study was straightforward. Psilocybin remains federally illegal in the United States, but a growing number of states and cities have moved to decriminalize it, and clinical research into psilocybin-assisted therapy has drawn intense public interest. Mental health professionals worried that this cultural momentum could encourage people with depression to treat psychedelics as a do-it-yourself substitute for therapy, medication, or both.
If that were happening at scale, the consequences could be serious. Major depression is a condition for which evidence-based treatments exist, and untreated or undertreated depression carries substantial risks. A population-level shift away from professional care would be a significant public health signal.
The new study found the opposite pattern. People with depression who used psilocybin sought mental health care at rates similar to those who did not use it, suggesting that psychedelic use is not crowding out conventional treatment in this group.
What the Data Showed
The headline results, as described by the research team, can be summarized as follows:
- Among people with depression, psilocybin users pursued mental health care at rates comparable to nonusers.
- Psilocybin users reported higher levels of unmet need for mental health care services.
- The pattern suggests people may be turning to psilocybin as an alternative or an adjunct to traditional therapy — but not as a full replacement for it.
- The findings are based on nationally representative survey data rather than a clinical trial, meaning they describe associations across the population rather than proving cause and effect.
Avery Eun, the study's first author and a second-year medical student at UC San Diego School of Medicine, framed the central result as encouraging news: people using psilocybin are not leaving conventional mental health care behind. But Eun also pointed to a puzzle inside the data. Even though psilocybin users access care at the same rate as nonusers, they still report that their needs are not being met — a gap the research team says deserves closer study.
The Paradox of Unmet Need
The unmet-needs finding is arguably the most intriguing element of the study. If psilocybin users are showing up for care at normal rates, why do they feel less served by the system than their peers who do not use the compound?
Several explanations are plausible, though the survey data alone cannot settle which is correct. People who seek out psilocybin may have depression that has proven difficult to treat with standard options, leaving them with a sense that available services fall short. They may also be pursuing emerging or experimental approaches precisely because conventional care has not delivered the relief they hoped for. Alternatively, they may face practical barriers — cost, wait times, limited provider networks, or stigma — that shape how well their care meets their expectations.
What the study does establish is that the unmet need is real and measurable in a nationally representative sample. That gives researchers and health systems a concrete target: understanding what these patients feel is missing and whether services can be adapted to close the gap.
What It Means for Patients and Providers
For clinicians, the takeaway is nuanced rather than reassuring in a simple way. The feared scenario — patients quietly dropping out of care to self-medicate — does not show up in these national numbers among people with depression. But the presence of elevated unmet need suggests that some psilocybin users are not fully satisfied with the treatment they receive, even as they continue to engage with it.
That combination could be useful clinically. If a patient discloses psilocybin use, it may be a signal worth exploring rather than a red flag indicating disengagement. It could mean the person is actively looking for something more from treatment — a different therapeutic approach, better symptom control, or simply a conversation about how psychedelics fit into their overall care.
For policymakers weighing decriminalization and the regulation of psychedelic-assisted therapy, the study offers a data point in a debate that has often run on speculation. The evidence so far does not support the idea that loosening psilocybin restrictions automatically pushes people with depression away from professional care.
Questions the Study Cannot Answer
The study's design comes with inherent limits. The NSDUH relies on self-reported information gathered through a survey, which means respondents describe their own substance use and mental health care rather than having either verified independently. That leaves room for recall error and for underreporting of illegal substance use.
The data also describe patterns at a single point in time, so they cannot establish whether psilocybin use changes someone's engagement with treatment over months or years. They cannot say whether psilocybin helped or harmed anyone's depression, what doses or settings were involved, or whether people combined psychedelic use with therapy, medication, or neither. And because the sample includes a broad age range starting at 12, patterns may differ across adolescents and adults in ways the headline numbers do not capture.
What the study can do is establish a national baseline. It replaces assumption with measurement on a question that has shaped clinical anxiety for years, and it identifies unmet need among psilocybin users as a specific area for follow-up research.
The Bottom Line
People with depression who use psilocybin are not, as a group, turning away from mental health care. They show up at roughly the same rates as people who do not use it. But they are more likely to say that the care they receive does not fully meet their needs — a finding that shifts the conversation from fear of abandonment to a more practical question: how can the mental health system better serve patients who are already looking for help, and who may be experimenting with psychedelics along the way.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
